Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.90-1.7%$17.74$13.50▼$25.67$4.03B0.543.13 million shs5.81 million shsANIPANI Pharmaceuticals$94.92+0.9%$74.48$52.50▼$95.60$2.06B0.63375,174 shs523,839 shsANVSAnnovis Bio$2.29-1.8%$2.57$1.11▼$10.54$44.59M1.65439,693 shs68,633 shsLNTHLantheus$55.15-0.3%$68.17$47.25▼$118.21$3.75B0.151.20 million shs883,949 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-0.35%+0.58%-11.02%-15.40%-0.64%ANIPANI Pharmaceuticals+0.64%+2.41%+47.19%+54.59%+47.61%ANVSAnnovis Bio+1.08%-3.89%-6.57%-27.40%-72.28%LNTHLantheus+0.71%-0.66%-21.65%-30.57%-48.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.014 of 5 stars3.71.00.00.03.72.53.1ANIPANI Pharmaceuticals3.678 of 5 stars1.62.00.03.34.13.31.3ANVSAnnovis Bio2.0374 of 5 stars3.33.00.00.00.61.70.6LNTHLantheus4.8888 of 5 stars4.33.00.04.23.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6763.71% UpsideANIPANI Pharmaceuticals 3.10Buy$84.75-10.71% DownsideANVSAnnovis Bio 2.60Moderate Buy$17.33657.58% UpsideLNTHLantheus 2.67Moderate Buy$91.6066.09% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$94.008/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.007/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$474.17M8.51$0.53 per share31.89$1.67 per share10.12ANIPANI Pharmaceuticals$614.38M3.35$7.71 per share12.31$20.13 per share4.72ANVSAnnovis BioN/AN/AN/AN/A$0.94 per shareN/ALNTHLantheus$1.52B2.47$7.13 per share7.74$17.16 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8619.6524.49N/A44.06%41.01%28.47%11/6/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$0.77N/A22.55N/A-1.37%25.03%8.00%11/14/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)LNTHLantheus$312.44M$3.7614.678.74N/A17.82%34.06%19.10%11/5/2025 (Estimated)Latest ANIP, ADMA, ANVS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78ANIPANI Pharmaceuticals1.392.541.96ANVSAnnovis BioN/A7.657.65LNTHLantheus0.494.294.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%LNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%ANIPANI Pharmaceuticals12.70%ANVSAnnovis Bio20.80%LNTHLantheus2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableLNTHLantheus70067.99 million66.63 millionOptionableANIP, ADMA, ANVS, and LNTH HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lantheus Holdings, Inc. - LNTHSeptember 3 at 10:00 AM | prnewswire.comLantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2 at 11:15 AM | tmcnet.comVident Advisory LLC Raises Stock Holdings in Lantheus Holdings, Inc. $LNTHSeptember 2 at 6:25 AM | marketbeat.comFDA Accepts Lantheus Holdings, Inc. (LNTH)’ NDA for New PSMA Imaging AgentSeptember 2 at 6:15 AM | finance.yahoo.comDriehaus Capital Management LLC Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTHSeptember 2 at 5:56 AM | marketbeat.comLantheus Holdings, Inc. $LNTH Shares Sold by GMT Capital CorpSeptember 1 at 5:53 AM | marketbeat.comCreativeOne Wealth LLC Acquires 8,905 Shares of Lantheus Holdings, Inc. $LNTHAugust 31 at 5:31 AM | marketbeat.comBrokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $105.50August 30, 2025 | americanbankingnews.comEpoch Investment Partners Inc. Invests $35.55 Million in Lantheus Holdings, Inc. $LNTHAugust 29, 2025 | marketbeat.comCampbell & CO Investment Adviser LLC Makes New Investment in Lantheus Holdings, Inc. $LNTHAugust 29, 2025 | marketbeat.comLeerink Partners Maintains a Buy on Lantheus Holdings (LNTH) With a $99 PTAugust 29, 2025 | uk.finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 29, 2025 | marketbeat.com2 High-Growth Small-Cap Stocks Poised to Ride the Russell 2000 RallyAugust 28, 2025 | investing.comLantheus Holdings, Inc. $LNTH is Alpha Wave Global LP's 9th Largest PositionAugust 28, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Position in Lantheus Holdings, Inc. $LNTHAugust 28, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lantheus Holdings, Inc. - LNTHAugust 27, 2025 | prnewswire.comLantheus Holdings, Inc. $LNTH Shares Purchased by Comerica BankAugust 27, 2025 | marketbeat.comLantheus Holdings, Inc. $LNTH Shares Sold by Capital Fund Management S.A.August 27, 2025 | marketbeat.comLantheus Holdings, Inc. $LNTH Shares Sold by Northern Trust CorpAugust 27, 2025 | marketbeat.comAxiom Investors LLC DE Reduces Stock Position in Lantheus Holdings, Inc. $LNTHAugust 26, 2025 | marketbeat.comRaymond James Financial Inc. Sells 28,095 Shares of Lantheus Holdings, Inc. $LNTHAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025ANIP, ADMA, ANVS, and LNTH Company DescriptionsADMA Biologics NASDAQ:ADMA$16.90 -0.30 (-1.74%) Closing price 04:00 PM EasternExtended Trading$17.00 +0.11 (+0.62%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$94.92 +0.82 (+0.87%) Closing price 04:00 PM EasternExtended Trading$94.92 0.00 (-0.01%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$2.29 -0.04 (-1.80%) Closing price 03:59 PM EasternExtended Trading$2.30 +0.01 (+0.48%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Lantheus NASDAQ:LNTH$55.15 -0.14 (-0.25%) Closing price 04:00 PM EasternExtended Trading$55.15 0.00 (0.00%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
